Clinical Trial

A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the long-term safety of HRS-5965 capsules in patients with primary IgA nephropathy, and also to assess its efficacy in reducing 24-hour urinary protein and delaying the decline in eGFR in these patients.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-23
Trial Details
NCT Number NCT07582133
Lead Sponsor Chengdu Suncadia Medicine Co., Ltd.
Conditions Primary IgA Nephropathy
Enrollment 380 participants
Start Date 2026-07-06
Primary Completion 2029-07 (estimated)
Study Completion 2029-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-22